AF
RNAC icon

Allworth Financial’s Cartesian Therapeutics RNAC Stock Holding History

Allworth Financial’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.07K Buy
774
+648
+514% +$4.8K ﹤0.01% 3851
2026
Q1 		$775 Buy
+126
New +$898 ﹤0.01% 4639
2025
Q3 		– Sell
-15
Closed -$156 – 5024
2025
Q2 		$156 Buy
+15
New +$160 ﹤0.01% 4348

Other funds holding RNAC

Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Allworth Financial's RNAC Position: Q2 2026 in Review

Allworth Financial increased its Cartesian Therapeutics (RNAC) stake by 514% in Q2 2026, buying an estimated $4.8K and bringing the position to 774 shares worth $8.07K. The position accounts for ﹤0.01% of the portfolio, ranked #3851.

Allworth Financial first reported a position in RNAC in Q2 2025 and has held it in 3 quarters since. 95 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.

  • Allworth Financial held 774 shares of Cartesian Therapeutics worth $8.07K as of Q2 2026.
  • Allworth Financial bought 648 Cartesian Therapeutics shares in Q2 2026, an estimated $4.8K.
  • Cartesian Therapeutics made up ﹤0.01% of Allworth Financial's portfolio in Q2 2026, its #3851 holding.
  • Allworth Financial first reported a position in Cartesian Therapeutics in Q2 2025 and has held it in 3 quarters since.
  • 95 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.